Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 2b, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-06826647 IN PARTICIPANTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Next Previous
Trial Profile

A PHASE 2b, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-06826647 IN PARTICIPANTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ropsacitinib (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer

Most Recent Events

  • 06 Apr 2022 Primary endpoint (Change from Baseline of Participants With a Psoriasis Area and Severity Index 90 (PASI 90) Response for 100-mg and 400-mg ) has been met according to the results published in the Journal of the American Academy of Dermatology
  • 06 Apr 2022 Results evaluating efficacy/safety of TYK2 inhibitor, PF-06826647, in moderate-to-severe plaque psoriasis published in the Journal of the American Academy of Dermatology
  • 27 Aug 2021 Primary end point (Change from baseline of participants with a psoriasis area and severity index 90 response for 50mg and 100 mg) has not been met according to the published in the Journal of the American Academy of Dermatology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top